845816-02-6
845816-02-6 structure
- Name: Lexatumumab
- Chemical Name: Lexatumumab
- CAS Number: 845816-02-6
- Molecular Formula:
- Molecular Weight:
- Catalog: Signaling Pathways Apoptosis Apoptosis
- Create Date: 2018-12-01 17:15:25
- Modify Date: 2024-01-20 18:06:52
-
Lexatumumab (HGS-ETR 2) is a human agonistic TRAIL receptor 2 (TRAIL-R2, DR5, APO-2) IgG4κ type monoclonal antibody. Lexatumumab induces Apoptosis in malignant mesothelioma. Lexatumumab can be used for malignant pleural mesothelioma (MPM) research[1].
| Name | Lexatumumab |
|---|
| Description | Lexatumumab (HGS-ETR 2) is a human agonistic TRAIL receptor 2 (TRAIL-R2, DR5, APO-2) IgG4κ type monoclonal antibody. Lexatumumab induces Apoptosis in malignant mesothelioma. Lexatumumab can be used for malignant pleural mesothelioma (MPM) research[1]. |
|---|---|
| Related Catalog | |
| Target |
TRAIL-R2[1] |
| In Vitro | The combination of Cisplatin (HY-17394) with Lexatumumab synergistically inhibits the cell growth and enhanced apoptotic death[1]. Lexatumumab (0-10 µg/ml, 72 h) induces various degrees of cell death in the different melanoma cell lines[2]. Cell Viability Assay[2] Cell Line: Melanoma cell lines Concentration: 0.01, 0.1, 1.0 and 10.0 µg/ml Incubation Time: 72 h Result: Induced various degrees of cell death in the different cell lines. |
| In Vivo | Lexatumumab (10 mg/kg, i.v., twice a week) increases antitumor effect in vivo when combined with Dacarbazine (HY-B0078)[2]. Animal Model: FEMX-1 xenografts mice[2] Dosage: 10 mg/kg, 10 mg/kg+Dacarbazine (62.5 mg/kg once a week, i.p. injection) Administration: i.v., twice a week Result: Increased antitumor effect in vivo when combined with Dacarbazine (HY-B0078). Induced cleavage of livin into its truncated, proapoptotic form, a compound previously shown to accelerate apoptosis. |
| References |
| No Any Chemical & Physical Properties |